Biofrontera AG banner

Biofrontera AG
XETRA:B8F

Watchlist Manager
Biofrontera AG Logo
Biofrontera AG
XETRA:B8F
Watchlist
Price: 4.8219 EUR 0.98% Market Closed
Market Cap: €1.1m

Wall Street
Price Targets

B8F Price Targets Summary
Biofrontera AG

There are no price targets for B8F.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Biofrontera AG Competitors:
Price Targets
PTEN
Patterson-UTI Energy Inc
-19% Downside
SANA
Sana Biotechnology Inc
168% Upside
FBIZ
First Business Financial Services Inc
33% Upside

Revenue
Forecast

25% / Year
Past Growth
32% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
25% / Year
Past Growth
32% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 1 year the compound annual growth rate for Biofrontera AG's revenue is 25%. The projected CAGR for the next 2 years is 32%.

Operating Income
Forecast

239% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
239% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Biofrontera AG

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Net Income forecast
is not available for
Biofrontera AG
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is B8F's stock price target?
Not Available

B8F doesn't have any price targets made by Wall Street professionals.

What is Biofrontera AG's Revenue forecast?
Projected CAGR
32%

For the last 1 year the compound annual growth rate for Biofrontera AG's revenue is 25%. The projected CAGR for the next 2 years is 32%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett